EWSR1 and neoplasm: Currently, most therapeutic interventions in clinical trials either disrupt the interaction between FUS/EWSR1-DDIT3 fusion proteins and their target mRNAs, inhibit downstream signaling caused by dysregulated transcription, or target specific antigens expressed on the tumor cell surface.